Glanzmann thrombasthenia Medical Services in China

Glanzmann thrombasthenia (GT) is a rare, inherited autosomal recessive bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the αIIbβ3 integrin glycoprotein complex—also known as the fibrinogen receptor—on the platelet surface. This glycoprotein is essential for platelet binding to fibrinogen, von Willebrand factor, and other adhesive ligands during hemostasis; its dysfunction results in severely impaired platelet plug formation despite normal platelet counts and morphology. Pathogenesis stems from biallelic loss-of-function mutations in either ITGA2B (encoding αIIb) or ITGB3 (encoding β3), leading to absent, reduced, or nonfunctional αIIbβ3 receptors. As a consequence, patients exhibit prolonged bleeding time, mucocutaneous bleeding (e.g., epistaxis, gingival bleeding, menorrhagia), easy bruising, and excessive bleeding after trauma or surgery—though spontaneous deep tissue or intracranial hemorrhage is uncommon. GT is pan-ethnic but shows higher prevalence in populations with increased consanguinity, such as Middle Eastern, Indian, and Romani communities. Epidemiologically, GT affects approximately 1 in 1,000,000 individuals worldwide, with no gender predilection. Risk factors include parental consanguinity and family history of unexplained bleeding diathesis; genetic counseling and prenatal testing are recommended for at-risk families. Quality of life is significantly impacted: chronic anemia from recurrent bleeding may cause fatigue and reduced exercise tolerance; adolescents and women face psychosocial challenges related to menorrhagia and fear of surgical procedures; children often experience school absences due to bleeding episodes or prophylactic interventions. While GT is lifelong and currently incurable, supportive management—including antifibrinolytics (e.g., tranexamic acid), platelet transfusions (for major bleeding or surgery), recombinant activated factor VIIa (rFVIIa), and emerging therapies like gene editing and lentiviral gene therapy in clinical trials—enables most patients to achieve near-normal functional status. However, alloimmunization against αIIbβ3 following repeated platelet transfusions remains a serious complication, limiting future transfusion efficacy and increasing perioperative risk. Comprehensive care requires multidisciplinary coordination among hematologists, gynecologists, dentists, surgeons, and psychologists within specialized coagulation centers.

Glanzmann thrombasthenia (GT) is a rare, inherited autosomal recessive bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the integrin αIIbβ3 (glycoprotein IIb/IIIa) complex—the most abundant receptor on the platelet surface. This receptor is essential for fibrinogen- and von Willebrand factor–mediated platelet cross-linking during primary hemostasis. The fundamental cause of GT lies in biallelic pathogenic variants in either ITGA2B (encoding glycoprotein IIb, chromosome 17q21.32) or ITGB3 (encoding glycoprotein IIIa, chromosome 17q21.32), resulting in absent, markedly reduced, or functionally impaired αIIbβ3 expression. Over 250 distinct mutations have been identified—including missense, nonsense, splice-site, frameshift, and large deletions—with genotype–phenotype correlations demonstrating that null mutations typically correlate with severe disease (type I GT), while hypomorphic variants may yield milder presentations (type II or variant GT). Consanguinity significantly increases the risk of homozygous or compound heterozygous inheritance and is therefore a major genetic risk factor; population isolates (e.g., certain Middle Eastern, Indian, or Romani communities) exhibit higher carrier frequencies (up to 1:20 in some groups) due to founder effects. There are no acquired or environmental causes of true GT; however, several clinical scenarios may mimic or exacerbate its phenotype. For instance, drug-induced thrombocytopenia or functional inhibition—particularly by antiplatelet agents such as abciximab, eptifibatide, or tirofiban (which are monoclonal antibodies or peptidomimetics targeting αIIbβ3)—can produce transient GT-like bleeding, though this is pharmacologically induced and reversible. Similarly, severe uremia, myeloproliferative neoplasms, or dysproteinemias (e.g., multiple myeloma) may impair platelet function secondarily but do not constitute GT. Environmental factors do not initiate GT, yet they critically modulate bleeding risk and clinical severity. Trauma, surgery, dental extractions, menstruation, and childbirth serve as physiological triggers of hemorrhage due to the underlying hemostatic defect. Infections—especially those associated with fever or systemic inflammation—may transiently worsen bleeding through cytokine-mediated platelet activation exhaustion or endothelial perturbation. Poor oral hygiene and chronic gingivitis increase mucosal bleeding propensity, while uncontrolled hypertension elevates intravascular shear stress and microvascular rupture risk. Iron deficiency anemia, often secondary to chronic menorrhagia or gastrointestinal blood loss in affected females, can further compromise oxygen delivery and tissue repair capacity. Importantly, concomitant use of NSAIDs, aspirin, or anticoagulants (e.g., warfarin, DOACs) substantially amplifies bleeding diathesis and must be avoided unless rigorously justified and monitored. Nutritional deficiencies—particularly vitamin C (scurvy-related capillary fragility) or vitamin K (impairing coagulation factor synthesis)—are not etiologic but act as synergistic environmental modifiers. Pregnancy represents a unique risk period: although platelet counts usually remain stable, hormonal shifts, uterine vascular remodeling, and delivery-related trauma heighten hemorrhagic risk—especially postpartum. Peripartum management requires multidisciplinary coordination involving hematologists, obstetricians, and anesthesiologists, often incorporating platelet transfusions, antifibrinolytics (e.g., tranexamic acid), and recombinant factor VIIa in refractory cases. Notably, GT does not confer increased thrombotic risk despite profound platelet dysfunction; paradoxical thrombosis is exceedingly rare and generally linked to iatrogenic interventions (e.g., central lines, prolonged immobility) rather than intrinsic pathology. Lifelong surveillance for iron deficiency, dental complications, and psychosocial impacts of chronic bleeding is integral to comprehensive care. Genetic counseling is mandatory for affected individuals and carriers, with prenatal testing (chorionic villus sampling or amniocentesis) and preimplantation genetic diagnosis available for at-risk couples. Early molecular diagnosis enables anticipatory guidance, avoidance of high-risk procedures without prophylaxis, and timely intervention—thereby reducing morbidity and improving quality of life.

Glanzmann thrombasthenia (GT) is a rare, autosomal recessive inherited bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the αIIbβ3 integrin receptor (also known as glycoprotein IIb/IIIa), the most abundant platelet surface receptor essential for fibrinogen-mediated platelet cross-linking. As a primary platelet function defect, GT manifests predominantly with mucocutaneous bleeding, typically presenting in infancy or early childhood, though severity varies widely depending on residual αIIbβ3 expression and functionality.

Early symptoms commonly appear within the first year of life and include prolonged bleeding after circumcision, umbilical stump separation, or heel prick sampling. Infants may exhibit recurrent, unexplained bruising (ecchymoses), petechiae—especially following minor trauma or viral illness—and persistent oozing from minor lacerations or abrasions. Epistaxis is frequently among the earliest recurrent symptoms, often beginning between ages 2–5 years and occurring spontaneously or with minimal provocation. Oral mucosal bleeding—such as gingival oozing during teething or after dental procedures—is also common in toddlers and preschool-aged children. Parents may report excessive bleeding following routine immunizations (e.g., intramuscular injections) or minor surgical interventions like tonsillectomy or adenoidectomy, which can trigger life-threatening hemorrhage if unrecognized preoperatively.

Typical symptoms reflect the hallmark defect in primary hemostasis: impaired platelet plug formation despite normal platelet counts and morphology. Patients consistently demonstrate prolonged bleeding time (historically measured via Ivy or template methods, now largely replaced by more specific assays), absent or severely diminished platelet aggregation in response to all physiological agonists—including adenosine diphosphate (ADP), epinephrine, collagen, and ristocetin—while ristocetin-induced platelet agglutination remains intact (distinguishing GT from Bernard-Soulier syndrome). Clinically, this translates into recurrent, disproportionate mucocutaneous hemorrhage: spontaneous or trauma-induced epistaxis lasting >15 minutes; menorrhagia in adolescent and adult females, often leading to iron-deficiency anemia; gastrointestinal bleeding (e.g., melena or hematochezia) secondary to angiodysplasia or erosive lesions exacerbated by impaired platelet sealing; and postpartum hemorrhage. Hematuria may occur but is less frequent than in coagulation factor disorders. Notably, deep tissue hematomas, hemarthroses, and intracranial hemorrhage are exceedingly rare—differentiating GT from severe hemophilias—and when they do occur, they usually follow major trauma or surgery.

Accompanying symptoms often stem from chronic blood loss or treatment-related sequelae. Iron-deficiency anemia is prevalent, particularly in menstruating females and patients with recurrent GI bleeding, manifesting as fatigue, pallor, tachycardia, and reduced exercise tolerance. Chronic transfusion-dependent patients may develop alloimmunization against HLA or platelet-specific antigens (especially HPA-1a), resulting in refractoriness to platelet transfusions—a critical therapeutic challenge. Some individuals develop anti-αIIbβ3 antibodies following exposure to exogenous platelets or recombinant factor VIIa, further complicating management. Mild splenomegaly has been reported in a subset of patients, likely secondary to chronic immune activation or hypersplenism, though its clinical significance remains unclear. Psychosocial burden—including anxiety around injury, school-related restrictions, and reproductive concerns—is substantial and warrants integrated multidisciplinary care.

Complications arise primarily from acute hemorrhage or iatrogenic interventions. Life-threatening complications include massive epistaxis requiring nasal packing or embolization; post-tonsillectomy hemorrhage necessitating emergency surgical control; intracranial hemorrhage (rare but catastrophic, with mortality up to 10% in reported series); and postpartum hemorrhage leading to hysterectomy or maternal death. Chronic complications include severe iron-deficiency anemia with resultant cardiac strain (e.g., high-output heart failure in extreme cases), growth retardation in pediatric patients with recurrent bleeding and nutritional compromise, and transfusion-transmitted infections (now rare with modern screening) or iron overload in multiply transfused individuals. Alloimmunization significantly increases perioperative bleeding risk and limits therapeutic options, especially prior to major surgery. Delayed wound healing is not characteristic but may occur secondary to repeated hematomas or infection at bleeding sites.

Diagnosis relies on a stepwise laboratory approach. Initial screening includes complete blood count (CBC) revealing normal platelet count and morphology (no giant platelets), normal prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen level—effectively excluding coagulation factor deficiencies and von Willebrand disease. Platelet function testing is pivotal: light transmission aggregometry (LTA) demonstrates absent aggregation to ADP, epinephrine, collagen, and arachidonic acid, with preserved response to ristocetin (≥80% of normal). Flow cytometry is the gold standard for definitive diagnosis, quantifying surface expression of CD41 (αIIb) and CD61 (β3) antigens; GT subtypes are classified as type I (≤5% residual αIIbβ3), type II (6–20%), or variant (normal quantity but dysfunctional receptor). Genetic testing identifies biallelic pathogenic variants in ITGA2B or ITGB3 genes, enabling carrier detection, prenatal diagnosis, and genotype–phenotype correlation.

Differential diagnosis must exclude other inherited and acquired platelet disorders. Bernard-Soulier syndrome presents with macrothrombocytopenia, prolonged bleeding time, and absent ristocetin-induced agglutination—opposite to GT’s preserved ristocetin response. Platelet-type (pseudo) von Willebrand disease shows enhanced ristocetin-induced platelet aggregation and decreased plasma VWF, unlike GT. Autosomal dominant thrombocytopenia with absent δ-granules (e.g., Paris-Trousseau/Jacobsen syndrome) features thrombocytopenia and abnormal platelet ultrastructure. Acquired conditions such as drug-induced thrombocytopenia (e.g., abciximab, tirofiban), myelodysplastic syndromes with platelet dysfunction, or systemic lupus erythematosus with anti-platelet antibodies may mimic GT but lack familial history and show distinct laboratory profiles. Finally, mild forms of GT must be distinguished from constitutional platelet function defects of uncertain significance, requiring rigorous functional and molecular characterization to avoid misclassification.

Glanzmann thrombasthenia (GT) is a rare, autosomal recessive inherited bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the αIIbβ3 integrin receptor (glycoprotein IIb/IIIa), essential for fibrinogen-mediated platelet cross-linking. Patients present with mucocutaneous bleeding—epistaxis, gingival hemorrhage, menorrhagia, easy bruising—and prolonged bleeding after trauma or surgery; however, platelet counts and morphology remain normal. Diagnosis relies on clinical history, prolonged bleeding time, absence of platelet aggregation in response to ADP, epinephrine, collagen, and ristocetin (with preserved ristocetin-induced platelet activation), and definitive confirmation via flow cytometry or genetic testing for biallelic pathogenic variants in ITGA2B or ITGB3 genes. Management is multidisciplinary, coordinated by hematology specialists, and tailored to bleeding severity, surgical needs, and reproductive planning.

Conservative treatment forms the cornerstone of long-term GT management and emphasizes prevention and non-pharmacologic interventions. Patients must avoid antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel) and anticoagulants unless absolutely indicated and carefully monitored. Dental care requires prophylactic measures: routine oral hygiene, fluoride application, and early referral to hematologists before any invasive dental procedure. Topical hemostatic agents—including tranexamic acid mouthwash (5% solution, rinsed 3–4 times daily for 5–7 days pre- and post-procedure), nasal packing with oxidized cellulose or fibrin sealant, and pressure dressings—are routinely employed for minor bleeding. Hormonal therapy (e.g., combined oral contraceptives or levonorgestrel-releasing intrauterine systems) is first-line for menorrhagia in women of childbearing age, reducing menstrual blood loss by up to 50–70%. Iron supplementation is initiated promptly in cases of iron-deficiency anemia secondary to chronic blood loss. Comprehensive patient education—including recognition of warning signs (e.g., prolonged oozing, hematuria, melena), emergency contact protocols, and use of medical alert identification—is integral to conservative care.

Pharmacotherapy remains supportive rather than curative. Antifibrinolytics—particularly tranexamic acid (10–25 mg/kg orally three to four times daily, adjusted for renal function)—are the most widely used and effective agents for mucosal bleeding prophylaxis and perioperative management. Aminocaproic acid serves as an alternative but is less potent and associated with higher rates of gastrointestinal intolerance. Recombinant activated factor VII (rFVIIa; NovoSeven®) is the primary hemostatic agent for major bleeding or surgical procedures when platelet transfusions are unavailable or contraindicated (e.g., due to alloimmunization). Dosing ranges from 60–90 µg/kg IV bolus, repeated every 2–3 hours for 2–3 doses, or continuous infusion at 1.5–2.5 µg/kg/min for 12–24 hours. While highly effective, rFVIIa carries thrombotic risk (especially in elderly or immobilized patients) and requires careful risk-benefit assessment. Platelet transfusions remain critical for life-threatening hemorrhage or high-risk surgeries but are limited by alloimmunization—up to 30–50% of chronically transfused GT patients develop HLA or HPA antibodies, rendering subsequent transfusions ineffective. Therefore, transfusion should be reserved for emergencies and administered only after HLA-matched or crossmatched platelets are secured. Desmopressin (DDAVP) has inconsistent efficacy in GT and is not recommended outside investigational settings.

Surgical treatment is not disease-modifying but addresses complications or enables definitive interventions. Splenectomy is generally avoided in GT, as it does not correct the intrinsic platelet defect and may increase thrombotic risk without improving hemostasis. Hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option but is reserved for severe, refractory cases with life-threatening bleeding and a matched sibling donor due to significant morbidity (graft-versus-host disease, infection, transplant-related mortality ~15–25%). Gene therapy is under active investigation in preclinical and early-phase clinical trials but is not yet standard-of-care. Surgical procedures—including dental extractions, tonsillectomy, or gynecologic interventions—require meticulous preoperative planning: baseline platelet antibody screening, rFVIIa availability, and coordination with a specialized hemophilia/GT treatment center. Minimally invasive techniques and intraoperative hemostatic adjuncts (e.g., argon beam coagulation, topical thrombin, fibrin glue) are strongly preferred.

China offers distinct advantages in GT management, particularly through its nationally integrated Hemophilia Treatment Network (HTN), established under the National Health Commission. Over 120 designated HTN centers—including top-tier institutions such as Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—provide standardized, protocol-driven care aligned with WFH and ISTH guidelines. rFVIIa is approved and reimbursed under China’s National Reimbursement Drug List (NRDL) for GT since 2021, significantly improving access. Domestic biosimilar rFVIIa (e.g., SinoBiopharm’s SB-001) has reduced acquisition costs by ~40% compared to imported products. Furthermore, China’s centralized platelet donor registry and HLA-typing infrastructure facilitate rapid identification of compatible donors, mitigating alloimmunization risks. The Chinese Society of Hematology publishes biennial GT Clinical Practice Guidelines, incorporating real-world data from the China Hemophilia Registry, which now includes >1,800 GT patients—the largest national cohort globally. Telehematology platforms enable remote monitoring and urgent consultation across provinces, enhancing continuity of care in rural regions.

Recovery and long-term follow-up emphasize proactive, individualized strategies. Patients should undergo annual comprehensive assessments: CBC, ferritin, liver/kidney function, platelet antibody screening (if transfused), and psychosocial evaluation. Women require gynecologic surveillance every 6–12 months, including pelvic ultrasound and endometrial biopsy if abnormal uterine bleeding persists despite hormonal therapy. Vaccination against hepatitis A/B is mandatory prior to any transfusion exposure. Physical activity should be encouraged—swimming, walking, and cycling are low-risk—but contact sports (e.g., rugby, boxing) are contraindicated. Pregnancy necessitates preconception counseling, multidisciplinary care (hematologist, obstetrician, anesthesiologist), and delivery planning at a tertiary center with rFVIIa and HLA-matched platelets available; vaginal delivery is preferred over cesarean unless obstetric indications exist. Psychosocial support—including peer networks facilitated by the China Hemophilia Association and cognitive-behavioral therapy for anxiety related to bleeding episodes—is strongly recommended. With optimized care, life expectancy approaches normal, and quality of life markedly improves. Ongoing research into gene editing (e.g., CRISPR-Cas9 correction of ITGA2B in autologous CD34+ cells) and next-generation platelet mimetics promises transformative advances within the next decade.